How should Tesamorelin be stored and reconstituted?

Lyophilised Tesamorelin stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

Should I cycle Tesamorelin?

Standard cycle for Tesamorelin is 8–12 weeks of 1x daily subq 1-2 mg dosing via subq, followed by a 4 week complete off-period. The off-period is calibrated to Tesamorelin's ~30 min half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

How does Tesamorelin's half-life affect dosing?

Tesamorelin has a plasma half-life of ~30 min, which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under 1x daily subq dosing at 1-2 mg per dose explains the typical onset timeline for anabolic and recovery endpoints.

What are the safety considerations for Tesamorelin?

Site reactions, arthralgia, fluid retention. IGF-1 elevation; monitor. Pregnancy contraindicated. For anabolic and recovery use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. Tesamorelin's ~30 min pharmacokinetic profile and subq administration route influence the side-effect profile in predictable ways.

Home/ Compounds/ Tesamorelin

Tesamorelin

Body Composition

Athletes and performance coaches evaluating Tesamorelin for body composition focus on three measurable endpoints: lean mass, recovery capacity, and the rate of return to training intensity between sessions. Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage Stimulates pituitary GH release, raising IGF-1 and producing marked reduction in visceral adipose tissue with relative sparing of subcutaneous fat.. The 1-2 mg 1x daily subq protocol over the standard 8-12 week cycle, paired with training stimulus and nutritional adequacy, is where the body-composition response is generated.

Body Composition / Training Applications

StrengthFat LossRecoveryHyperplasiaInjury Recovery

Key Takeaways

Body composition lens: response to Tesamorelin is proportional to training stimulus and nutritional adequacy.
Mechanism: Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage.
Body composition dose: 1-2 mg 1x daily subq via subq; effects visible at week 4-8 with adequate training and protein.
Cycle structure: 8-12 weeks on, 4 weeks off; training-day or daily dosing depending on half-life.
Performance stack partners: IGF-1 LR3, CJC-1295 + Ipamorelin Blend, TB-500.

Body Composition / Training Mechanism

Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage. Stimulates pituitary GH release, raising IGF-1 and producing marked reduction in visceral adipose tissue with relative sparing of subcutaneous fat. The body composition layer follows: how the compound contributes to anabolic substrate, how it shapes the recovery window between training sessions, how training-day dosing differs from rest-day dosing, and which structural-adaptation dimension (hyperplasia or hypertrophy) is most affected by Tesamorelin.

Training-day versus rest-day dosing

Many peptides in this category respond better to training-day-only versus rest-day-included dosing. Tesamorelin with a ~30 min half-life of ~30 min is short-lived enough that timing relative to training sessions matters. The practical dosing schedule reflects this.

Hyperplasia and structural adaptation

Where Tesamorelin demonstrates effects on fibre count rather than fibre size — hyperplasia rather than hypertrophy — the structural adaptation matters more than the acute anabolic signal. Most peptides in this category contribute to the hypertrophic rather than hyperplastic adaptation, with the magnitude depending on training stimulus.

Recovery window and training frequency

The most reliably reported effect of Tesamorelin in athlete populations is on the recovery window between sessions. Faster connective tissue recovery, better sleep quality, and reduced systemic inflammation translate into more high-quality training days per cycle. This is the practical mechanism by which body composition shifts for most users — not via dramatic acute anabolic effect but via more accumulated quality training.

Body Composition / Training Applications

Recovery

For recovery, Tesamorelin integrates with training programming on a per-session and per-cycle basis. Training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The protocol pattern reflects training intensity and recovery demand.

Tendon Repair

The body composition community converges on Tesamorelin for tendon repair with reported best-fit cycles of 8–12 weeks. Off-cycle of 4 weeks is standard. Stacking with complementary peptides on different pathways is the typical pattern for advanced users.

Strength

Strength responds to Tesamorelin with effect sizes proportional to training stimulus and nutritional adequacy. Users running aggressive caloric deficits see reduced response; users in surplus with adequate protein see proportionally larger response. Programming the inputs is half the protocol.

Joint Health

For joint health, Tesamorelin integrates with training programming on a per-session and per-cycle basis. Training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The protocol pattern reflects training intensity and recovery demand.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	1-2 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1-2 mg	4–6 weeks initial cycle
Body Composition focus	SubQ	1-2 mg	1x daily SubQ
Maintenance phase	SubQ	1-2 mg	Ongoing with periodic pauses

Dose timing for Tesamorelin is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.

Stacking

Tesamorelin stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from performance coaches and athletes.

Tesamorelin + IGF-1 LR3: Binds the IGF-1 receptor with full agonist activity. Pairs naturally with Tesamorelin's mechanism in body composition / training protocols.
Tesamorelin + CJC-1295 + Ipamorelin Blend: CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. Pairs naturally with Tesamorelin's mechanism in body composition / training protocols.
Tesamorelin + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Tesamorelin's mechanism in body composition / training protocols.
Tesamorelin + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Tesamorelin's mechanism in body composition / training protocols.

Safety & Regulatory Status

WADA: Banned (S2) FDA: Approved (Egrifta 2010 for HIV lipodystrophy)

Site reactions, arthralgia, fluid retention. IGF-1 elevation; monitor. Pregnancy contraindicated.

Lens-specific safety considerations for body composition / training use of Tesamorelin: Site reactions, arthralgia, fluid retention. IGF-1 elevation; monitor. Pregnancy contraindicated. Additional body composition / training monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Tesamorelin for HIV-associated lipodystrophy

PMID 20581419

Supporting

Tesamorelin visceral fat reduction mechanism

PMID 24247738

Tesamorelin vs Related Peptides

Compound	Profile	Onset	Best For
Tesamorelin	Stabilised GHRH analogue	~30 min	Body Composition
IGF-1 LR3	Modified insulin-like growth factor 1	~20-30 hr (vs ~10 min for native IGF-1)	A modified IGF-1 with a 13-amino-acid N-terminal extension and Arg substitution that resists IGFBP binding — extending half-life from 10 minutes to roughly a day
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite

Frequently Asked Questions

Effect timeline for body composition?

Acute pump and recovery effects within 1–2 weeks. Visible body composition shifts at 4–8 weeks for trained users with adequate nutrition. Peak effect at the end of a 12-week cycle; partial regression during the 4-week off-period. Total trajectory is incremental rather than dramatic.

Training-day only or daily dosing?

For most peptide compounds with short-to-moderate half-life, training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The choice depends on the user's training volume and the compound's pharmacokinetics. Daily dosing for 4-7 days is the default; training-day-only protocols are appropriate for lower-volume programmes.

Can I use Tesamorelin alongside creatine, protein, and standard supplements?

Yes — peptide protocols are fully compatible with the standard supplement stack. Creatine, protein powder, beta-alanine, citrulline, and the like operate on entirely separate mechanisms and are additive. Pre-workout stimulants and high-caffeine intake are also compatible.

Will Tesamorelin affect my training performance?

Most commonly via faster recovery between sessions, which permits higher training frequency and intensity. Acute performance-enhancing effects in a single session are not the typical profile. Users typically need to upregulate nutrition and adjust programming to take advantage of the increased recovery capacity.

What is the regulatory status of Tesamorelin?

Tesamorelin regulatory status: Approved (Egrifta 2010 for HIV lipodystrophy) in the United States; WADA status banned (s2); research level research level investigational. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For anabolic and recovery use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

What does Tesamorelin stack well with?

For body composition / training protocols, Tesamorelin pairs with compounds on complementary pathways: IGF-1 LR3, CJC-1295 + Ipamorelin Blend, TB-500. These pairings are selected because they engage independent receptor systems from Tesamorelin's primary mechanism (Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage), producing additive or synergistic effects rather than receptor competition.

Clinical Protocol

Start a Tesamorelin Protocol

Alukard provides physician-supervised body composition protocols with GMP-certified Tesamorelin and GMP-certified compounds and training-aware dosing guidance.

Get Protocol

Quick Facts

Molecular weight: 5135 Da
Sequence length: 44 aa
Half-life: ~30 min
WADA: Banned (S2)
FDA: Approved (Egrifta 2010 for HIV lipodystrophy)

Stack Partners

IGF-1 LR3

CJC-1295 + Ipamorelin Blend

TB-500

BPC-157

Tesamorelin + Ipamorelin Blend

Research Note

All body composition / training applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Tesamorelin unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised body composition protocols

Start Your Body Composition / Training Protocol for Tesamorelin

Alukard provides physician-supervised body composition protocols with GMP-certified compounds and training-aware dosing guidance.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised